| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
There are many reports so far for using host’s lipid metabolism for a hepatitis C virus (below HCV) and making the environment of the replication and infection profitable. It was considered whether the anti-viral effect could be expected by miRNA-33, which participates in lipid metabolism, restraining replication and infection of an HCV, but the effect wasn't indicated. On the other hand, the expression of miRNA-27 was accelerated in the liver of non-alcoholic steatohepatitis hepatitis (NASH) patients. This miRNA-27 can be a marker of improvement for fibrosis in HCV patients after treatment.
|
